Hypometilating Agents (Hma) As Salvage Therapy In Relapsed Or Refractory Aml: A 5-Center Retrospective Study

Introduction: 5-azacytidine and decitabine have been widely studied as first line chemotherapy in acute myeloid leukemia (AML) patients not eligible for allogenic stem cell transplantation, but data on their use as salvage chemotherapy are limited. We tried to define efficacy and feasibility of hypometilating agents (HMA) as salvage chemotherapy in patients without previous allogenic stem cell transplantation.